Pharmaceutical Supply Chain Planning During Pandemics
Evidence suggests that the likelihood of pandemics or other natural disasters has increased over the past century because of increased global travel and integration, urbanization, changes in land use, and greater exploitation of the natural environment.
At Bora, we understand that your product supply is critical to the on-going success of your company and planning for supply continuity of your products in many types of disasters is a key responsibility of not only you but also of your manufacturing partner.
It is likely that these trends will continue and will intensify for some time to come.
In this Guide, you will explore:
- Why bringing back the supply of chemicals and APIs to individual nations will be extremely difficult
- Why firms need to innovate, change, and have in place quality risk management strategies
- What the risk assessment should look at to determine needs such as safety stock, building reactive capacity, automation, cross-training, and more
- Why companies should focus on manufacturing locations known to have financial stability, full supply chain capabilities and have established contingency plans
- Why the components of a good contingency plan should include the following: Scenarios, Triggers, Response, Who to Inform, Key Responsibilities, and a Timeline
Want to learn how we at Bora think about the current COVID-19 situation and how we plan for contingencies? Download our comprehensive whitepaper to explore how.